TRANSCRIPTION FACTOR PROTEIN EXPRESSION PATTERNS BY NEURAL OR NEURONAL PROGENITOR CELLS OF ADULT MONKEY SUBVENTRICULAR ZONE

A. B. TONCHEV, a,b T. YAMASHIMA, a,* K. SAWAMOTOC,d AND H. OKANOd

aDepartment of Restorative Neurosurgery, Division of Neuroscience, Kanazawa University Graduate School of Medical Science, Takaramachi 13-1, Kanazawa 920-8641, Japan
bDivision of Cell Biology, Department of Forensic Medicine, Varna University of Medicine, 55 Marin Drinov str, BG-9002 Varna, Bulgaria
cBridgestone Laboratory of Developmental and Regenerative Neuroscience, Keio University School of Medicine, Tokyo, Japan
dDepartment of Physiology, Keio University School of Medicine, Tokyo, Japan

Abstract—The anterior subventricular zone of the adult mammalian brain contains progenitor cells which are upregulated after cerebral ischemia. We have previously reported that while a part of the progenitors residing in adult monkey anterior subventricular zone travels to the olfactory bulb, many of these cells sustain location in the anterior subventricular zone for months after injury, exhibiting a phenotype of either neural or neuronal precursors. Here we show that ischemia increased the numbers of anterior subventricular zone progenitor cells expressing developmentally regulated transcription factors including Pax6 (paired-box 6), Emx2 (empty spiracles-homeobox 2), Sox1–3 (sex determining region Y-box 1–3), Ngn1 (neurogenin 1), Dlx1,5 (distalless-homeobox 1,5), Olig1,3 (oligodendrocyte lineage gene 1,3) and Nkx2.2 (Nk-box 2.2), as compared with control brains. Analysis of transcription factor protein expression by sustained neural or neuronal precursors in anterior subventricular zone revealed that these two cell types were positive for characteristic sets of transcription factors. The proteins Pax6, Emx2, Sox2,3 and Olig1 were predominantly localized to dividing neural precursors while the factors Sox1, Ngn1, Dlx1,5, Olig2 and Nkx2.2 were mainly expressed by neuronal precursors. Further, differences between monkeys and non-primate mammals emerged, related to expression patterns of Pax6, Olig2 and Dlx2. Our results suggest that a complex network of developmental signals might be involved in the specification of primate progenitor cells. © 2006 Published by Elsevier Ltd on behalf of IBRO.

Key words: cerebral ischemia, primate, adult neurogenesis, cell fate, developmental signal.

*Corresponding author. Tel: +81-76-265-2381; fax: +81-76-234-4264. E-mail address: yamashim@med.kanazawa-u.ac.jp (T. Yamashima).

Abbreviations: BrdU, 5-bromo-2′-deoxyuridine; CNP, 2′,3′-cyclic nucleotide 3′-phosphodiesterase; Dlx, distalless-homeobox; Emx, empty spiracles-homeobox; GFAP, glial fibrillary acidic protein; NgN, neurogenin; Nkx, Nk-box; Olig, oligodendrocyte lineage gene; Pax, paired-box; Sox, sex determining region Y-box; SVZa, anterior subventricular zone; TRITC, tetramethylrhodamine isothiocyanate.
Fig. 1. Schematic presentation of BrdU/Ki67 paradigm and the investigation of transcription factor expression by progenitor cells in SVZa. BrdU infusion (gray bar) was performed between days 5–9 (D5–D9) after surgery, and the fate of BrdU+ cells in SVZa was investigated on D9 (short-term interval) or at long-term intervals (D23, D44 and D79; D23 and D44 are omitted for clarity). As Ki67 selectively labels the proliferating cells at time of animal kill (arrows), at the D9 time-point almost all BrdU+ cells are also Ki67+, while at the long-term intervals after surgery only few BrdU+ are co-labeled by Ki67. Cellular phenotypes characterized by their positivity for BrdU/Ki67 and Musashi1/III-tubulin (neural/neuronal) were investigated for putative expression of either early- or lineage-selective transcriptional regulators of embryonic brain development.

EXPERIMENTAL PROCEDURES

Monkeys

Animal experiments were performed under the guidelines of the Animal Care and Ethics Committee of Kanazawa University, and the NIH Guide for the Care and Use of Laboratory Animals. Throughout the experiments, all efforts were made to minimize the number of animals used, and their suffering. Sexually mature female Japanese monkeys (*Macaca fuscata*) (*n*=14) were bred in air-conditioned cages, and were allowed free daily access to food and water. Transient global cerebral ischemia was performed under general inhalation anesthesia with artificial ventilation as previously described (Yamashima, 2000; Yamashima et al., 1998; Tonchev et al., 2005). Briefly, after resecting the sternum, the innominate and left subclavian arteries were transiently clipped for 20 min. The effectiveness of clipping was demonstrated by an almost complete absence (0.5±1.0 ml/100 g brain/min) of cerebral blood flow being monitored by laser Doppler (Vasamedics, St. Paul, MN, USA). Ischemia was performed to eight macaques, while six macaques underwent sham surgery (executed by opening the chest without vessel clipping). All monkeys received five daily injections of 100 mg/kg i.v. of BrdU (Sigma-Aldrich Japan K.K., Tokyo, Japan), performed on days 5–9 after surgery. Respective animals were then killed on day 9 (*n*=2), day 23 (*n*=2), day 44 (*n*=2) and day 79 (*n*=2) after ischemia or on day 9 (*n*=2), day 23 (*n*=2) and day 44 (*n*=2) after the sham operation (Tonchev et al., 2005).

Tissue processing

The monkeys were killed by intracardial perfusion with 4% paraformaldehyde under general anesthesia. The brains were removed, and tissue blocks (ac +7 mm anteriorly to ac +1 mm posteriorly) were cryoprotected in sucrose, and frozen in O.C.T. medium (Tissue-Tek, Sakura Finetech Co, Tokyo, Japan), and serially cut into 40-μm thick coronal sections. All stainings were performed on free-floating sections. To reveal BrdU incorporated into the cells, DNA was denatured by treatment with formamide and HCl as described (Eriksson et al., 1998; Tonchev et al., 2003), followed by application of mouse anti-BrdU (1:100, Becton Dickinson, San Jose, CA, USA) or rat anti-BrdU (1:100, Harlan Sera-Laboratory, Loughborough, UK) antibodies. We used the following antibodies for phenotypic markers: mouse anti-Ki67 (1:50, Novoceastra, Newcastle, UK), rat anti-Musashi1 (1:100, Kaneko et al., 2000), rabbit anti-Musashi1 (1:200, Chemicon, Temecula, CA, USA), rabbit or mouse anti-Nestin (1:200, Chemicon), mouse anti-NeuN (1:100, Chemicon), rabbit or mouse anti-β-tubulin class III (1:400, Covance, Richmond, CA, USA), goat anti-Doublecortin (1:200, Santa Cruz Inc., Santa Cruz, CA, USA), mouse anti-β3-c-cyclic nucleotide 3'-phosphodiesterase (CNP) (1:400; Chemicon), and anti-NeuN (1:200, Chemicon).
and rabbit anti-gial fibrillary acidic protein (GFAP) (1:400, Sigma). The following rabbit polyclonal antibodies against transcription factors were obtained from Chemicon: Esm2 (1:400), Ngn1 (1:2000), Ngn2 (1:1500), Ngn3 (1:100–1:1000), Dlx1 (1:500), Dlx2 (1:200), Dlx5 (1:1000), Sox1 (1:200), Sox2 (1:200), Sox3 (1:200), Olig1 (1:1000), Olig3 (1:300), Nkx2.2 (1:400). The rabbit Pax6 antibody (1:200) was from Covance, and the rabbit anti-Olig2 antibody was a gift from Hirohide Takebayashi (National Institute for Physiological Sciences, Okazaki, Japan).

The primary antibodies were revealed by appropriate secondary antibodies conjugated to AlexaFluor 488, 546, or 633 (Molecular Probes, Eugene, OR, USA), tetramethylrhodamine isothiocyanate (TRITC; Jackson Immunoresearch, West Grove, PA, USA), or to biotin for immunoperoxidase labeling (1:30–1:100; Vector ABC kit, Vector Laboratories, Burlingame, CA, USA). For double- and triple-staining, the respective primary antibodies were from different species, and were applied sequentially to minimize the probability for cross-reactivity. Negative control experiments were performed by omitting the primary antibody and these revealed no positive staining.

Image analysis

Double- and triple-labeling to determine the expression of transcription factors by BrdU-labeled cells or cells labeled for particular phenotypic markers was evaluated using confocal laser scanning microscopy (LSM 510, Carl Zeiss, Tokyo, Japan). Alexa Fluor 488 was appointed in the green channel, TRITC or Alexa Fluor 546, in the red channel, and Alexa Flour 633, in the blue channel. Each fluorochrome was scanned separately and sequentially to minimize the probability of signal transfer among channels. Z sectioning at 0.5–1 μm intervals was performed and optical stacks of at least 20 images were used for analysis. Digital three-dimensional reconstructions were created by the Zeiss LSM software version 2.3. Within each animal group, at least 150 cells positive for BrdU or a phenotypic marker were sampled for co-expression with respective transcription factors. The absolute numbers of transcription factor/BrdU double-positive cells were determined by multiplying the corresponding fractions with the total numbers of BrdU− cells evaluated on every 12th section stained by the peroxidase method within grids of 800 μm×100 μm placed in the dorsal, ventral, and striatal aspects of SVZa (see Fig. 2A) as previously described (Tonchev et al., 2005). Numbers and percentages were averaged to obtain a mean density value for each transcription factor/animal group.

Statistical analysis

For comparing percentages of cells expressing certain transcription factor, we applied nonparametric tests (Mann-Whitney U test and Kruskal-Wallis test) or one-way ANOVA followed by Tukey-Kramer’s post hoc comparisons. Data were expressed as mean ± S.E.M. Differences were considered significant when P < 0.05.

RESULTS

Expression of Pax6, Emx2 and Sox proteins by SVZa progenitors

Immunohistochemical staining for the transcription factors Pax6, Emx2, and Sox1–3 revealed numerous positive cells, frequently in clusters, located along the walls of the anterior horn of the lateral ventricle (Fig. 2A, arrows), the zone that contains proliferating (BrdU−) precursor cells in the adult mammalian brain (Fig. 2A, arrowheads). At the early post-BrdU time-point (day 9 after surgery, 2 h after the last BrdU injection), most (75–85%) BrdU− cells in SVZa co-expressed Pax6 (Fig. 2B, 2F1), Emx2 (Fig. 2C, 2F2) and Sox2,3 (Fig. 2F4, F5). The Sox1+/BrdU− cells composed about half of the BrdU+ cells (Fig. 2D, 2F3). At a late post-BrdU survival time-point (day 44 after surgery, 5 weeks after the last BrdU injection), many of the BrdU+ cells that had retained their presence in SVZa revealed negativity for the transcription factors (Fig. 2E, arrows). The percentage of BrdU− cells expressing Pax6, Emx2 or Sox2,3 decreased with a statistical significance (P < 0.05, Kruskal-Wallis test), while the Sox1+/BrdU co-labeling sustained its value (Fig. 2F). While no statistically significant difference was found between sham-operated and ischemic brains with respect to the percentage of BrdU+ cells expressing the five transcription factors (Fig. 2F), the absolute numbers of BrdU/transcription factor double-positive cells in postischemic SVZa was significantly greater than in the controls (Fig. 2G).

To investigate the progenitor cell type(s) expressing Pax6, Emx2 and Sox1–3, we performed co-labeling with Musashi1, a marker of neural progenitor cells (Kaneko et al., 2000), and with βIII-tubulin or Doublecortin, markers of progenitors committed to neuronal lineage (neuronal progenitors) (Pencea et al., 2001; Gleseson et al., 1999). We observed that Pax6 (Fig. 3A, 3H1), Emx2 (Fig. 3B, 3H2) and Sox2,3 (Fig. 3C, 3H3) co-stained exclusively with Musashi1 in both ischemic and sham-operated animals. Co-labeling with neuronal progenitor markers (Fig. 3D) was negligible for these four transcription factors (<1% of the Pax6−, Sox2,3−, and <5% of the Emx2− cells). In contrast, Sox1 co-labeled mostly with βIII-tubulin (Fig. 3F, 3H4), while less than 3% of the Sox1− cells co-expressed Musashi1 (Fig. 3E, 3H4). The transcription factor-positive clusters remained negative for GFAP (Fig. 3G).

Differential transcription factor expression by sustained proliferating progenitors

We have previously documented the existence of long-term BrdU-retaining cells in SVZa that have incorporated BrdU early after ischemia and preserved an immature phenotype and location in SVZa for months after injury (Tonchev et al., 2005; see Fig. 1). Most of these BrdU+ cells expressed βIII-tubulin indicating neuronal differentiation, while a few were positive for Musashi1 and Ki67 suggesting they were neural progenitors in active phases of their cell cycle (Tonchev et al., 2005). We investigated whether BrdU/Ki67 double-positive cells co-express transcription factors at long-term time-points after ischemia/BrdU. Triple-labeling for BrdU, Ki67 and the five transcription factors on postischemic days 44 or 79 (5 or 10 weeks after BrdU, respectively) revealed that the vast majority of the BrdU+/Ki67+ cells in SVZa were co-labeled for Emx2 (Fig. 4A; 47 of 53 BrdU+/Ki67+ cells), Pax6 (Fig. 4B; 43 of 51), Sox2 (Fig. 4C; 50 of 55) or Sox3 (51 of 57). In contrast, Sox1 expression was not found in BrdU+/Ki67+ cells (Fig. 4D). Additional experiments provided direct evidence that the Ki67+ cells were Musashi1+ (Fig. 4E, arrowheads) but negative for βIII-tubulin (Fig. 4E, arrows), and that Musashi1 was expressed by sustained BrdU+/Sox3+ cells (Fig. 4F), and similarly, by sustained BrdU+/
Fig. 2. Expression of Pax6, Emx2 and Sox proteins by BrdU⁺ cells in monkey SVZa. (A) Low magnification micrographs showing the overall distribution of Pax6 (A1) and BrdU (A2) positive signals in SVZa, and overlay (A3). The position of the anterior horn of the lateral ventricle (LVa) sampled in A1–A3 is depicted on the schematic map (A4). Note that both Pax6⁺ cells (arrows) and BrdU⁺ cells (arrowheads) are preferentially located along the walls of LVa, not in the parenchyma. The images are representative also for the other four transcription factors. Str., striatal SVZa. (B) High
Sox2⁺, BrdU⁺/Pax6⁺ and BrdU⁺/Emx2⁺ cells (data not shown).

Expression of Ngn proteins by SVZa progenitors

Double-labeling for BrdU and Ngn1 (Fig. 5A) or Ngn2 (Fig. 5B) revealed contrasting findings. The Ngn1⁺/BrdU⁺ cells comprised a significant proportion of the BrdU⁺ cells (60–70% on day 9; 35–40% on day 44), while the Ngn2⁺/BrdU⁺ cells were few (less than 5% of the BrdU⁺ cells on day 44) (Fig. 5C1, 5C2). The Ngn1⁺/BrdU⁺ cells were typically grouped within a larger Ngn1⁺ cluster (Fig. 5A, box). The rare Ngn2⁺/BrdU⁺ cells were entangled in the BrdU⁺ clusters (Fig. 5B4–5B6, arrows) as were some Ngn2⁺/BrdU⁻ cells (Fig. 5B4–5B6, arrowheads). No statistically significant difference was found between sham-operated and ischemic brains with respect to the percentage of BrdU⁺/Ngn⁻ cells, while the absolute numbers of BrdU⁺/Ngn1⁺ (but not BrdU⁺/Ngn2⁺) cells in postischemic SVZa were significantly greater than in the controls (Fig. 5C3, 5C4). A third member of the family, Ngn3, was not found to be expressed in SVZa in our experiments (data not shown).

Expression of Olig proteins by SVZa progenitors

Double-staining for BrdU and Olig1 or Olig3 demonstrated that the two transcription factors extensively co-labeled with BrdU on day 9 (Fig. 7A), while at long-term survival (day 44) the percentage of co-staining with BrdU significantly decreased (Fig. 7B, 7E1, 7E2). In contrast, Olig2⁺ clusters (Fig. 7C, arrows) did not co-label with BrdU (Fig. 7C, arrowheads), and only single weakly labeled Olig2⁺ cells rarely co-stained with BrdU (<1% of the BrdU⁺ cells). We also investigated Nkx2.2, a factor that is also involved in the control of oligodendrogenesis in both embryonic and adult brain (Rowitch, 2004; Fancy et al., 2004). Similarly to Olig1,3, Nkx2.2 (Fig. 7D) extensively co-labeled with BrdU at short-term survival time-points, while at long-term survival (day 44) the percentage of co-staining with BrdU decreased (Fig. 7E3) with a statistical significance (P<0.05, Kruskal-Wallis test). The percentage of Nkx2.2/BrdU co-labeling (45–50%) was significantly higher than the percentage of Olig1/BrdU or Olig3/BrdU co-labeling (10–15%) (P<0.01, Kruskal-Wallis test). The absolute numbers of BrdU⁺/Olig1⁺ (Fig. 7E4), BrdU⁺/Olig3⁺ (Fig. 7E7) and BrdU⁺/Nkx2.2⁺ (Fig. 7E6) cells in postischemic SVZa were significantly greater than in the controls.

Dual immunohistochemical staining with Musashi1 resulted in co-labeling with Nkx2.2, Olig1 and Olig3 (Fig. 7F, 7J), but not with Olig2 (data not shown). On the other hand, Olig3 and Nkx2.2 (but not Olig1 or Olig2) co-stained with βIII-tubulin in SVZa (Fig. 7G, 7J), while Nkx2.2 and Olig2 co-labeled with the oligodendrocyte marker CNP (Braun et al., 1988) in the adjacent striatal parenchyma (Fig. 7H). At long-term survival time-points after BrdU Olig1 (but not
Fig. 3. Co-labeling of Pax6, Emx2 and Sox proteins with progenitor cell markers. (A) Double-staining for Pax6 (A1) and Musashi1 (Msi1, A2), and overlay (A3), on day 9. Two regions (depicted in frames) in the low magnification micrograph are shown in magnification in the insets. The upper inset demonstrates that despite extensive co-labeling, single-labeled cells were also observed (arrowheads). The lower inset (A4–A6) shows confirmation of double-staining by computer-generated orthogonal projections. (B) Double-staining for Emx2 (B1) and Musashi1 (B2), and overlay (B3), on day 9. (C) Double-staining for Sox2 (C1) and Musashi1 (C2), and overlay (C3), on day 44. (D) Double-staining for Pax6 (D1; a positive “doublet” is depicted...
DISCUSSION

Mechanisms that specify the fate of embryonic neural precursors might be at least in part recapitulated in the adult brain (Gotz, 2003; Alvarez-Buylla and Lim, 2004). This concept was supported by data in rodents showing that transcriptional regulators of embryonic precursors were also expressed by adult SVZa progenitors: Pax6 and Olig2 (Hack et al., 2004), Emx2 (Galli et al., 2002), Dlx2 (Doetsch et al., 2002), and Sox2 (Ferri et al., 2004; Komitova and Eriksson, 2004). We first report expression of developmentally-regulated transcription factors at protein level by SVZa progenitor cells of adult primate brain. Ischemia increased the absolute numbers of BrdU+/Ki67− cells expressing the proteins Pax6, Emx2, Sox1−3, Ngn1, Dlx1,5, Olig1,3, and Nkx2.2 as compared with controls (Fig. 8A). The decrease of BrdU/transcription factor co-labeled cells at long-term as compared with short-term time intervals reflects the global decrease of labeled progenitor cells in SVZa over time (Tonchev et al., 2005) as the precursor cells migrate away from SVZa toward the olfactory bulb. Notably, ischemia did not affect the percentage of BrdU/ transcription factor double-labeled cells as compared with controls. These data are compatible with our previous

by an arrow) and Doublecortin (DCX) (D2; arrowheads), and overlay (D3), on day 23. (E) Double-staining for Sox1 (E1, arrow depicts a positive cluster) and Musashi1 (E2; arrowhead), Ki67 (E3), and overlay (E4), on day 44. Ki67 co-labels with Musashi1 (arrowheads), not with III-tubulin (arrows). (F) Triple-labeling for Sox3 (F1), Musashi1 (F2) and BrdU (F3), and overlay (F4), on day 79. Triple-stained cells are depicted by arrows. Scale bar=20 μm. Asterisk, lateral ventricle.

Olig2, Olig3 or Nkx2.2, data not shown) co-labeled with Ki67 (Fig. 6I).
results showing no change in the percentage of BrdU/Musashi1 or BrdU/jIlIII-tubulin co-labeling between postischemic and control SVZa. Altogether, our findings suggest that ischemia increases the progenitor cell proliferation and absolute numbers without affecting progenitor differentiation, and in particular neuronal differentiation.

Despite the decrease of progenitors in SVZa over time, a significant proportion of these cells remained in SVZa for at least three months after ischemia. Immunophenotype analysis of these sustained cells revealed two distinct cell populations, each with a characteristic transcription factor expression pattern at protein level (Fig. 8B). The segregation of transcriptional regulators expressed by adult monkey neural or neuronal progenitors (Fig. 8B) suggests that a set of transcription factors might define a specific cell phenotype, similarly to the developing brain. Notably, the localization of some of the examined factors in either neuronal (jIlIII-tubulin) or neural (Musashi1) precursors was not strictly selective as cells positive for Dlx1,5, Ngn1, Nkx2.2 or Olig3 were co-labeled not only for jIlIII-tubulin, but also for Musashi1. At the same time, these cells were negative for Ki67 at long-term time-points, indicating that the Musashi1 cells co-labeled for Dlx1,5, Ngn1, Nkx2.2 or Olig3 at long-term time points were non-mitotic cells. These could be quiescent progenitors not in active cell cycle at the time of animal perfusion. Accordingly, we have previously demonstrated that Musashi1/GFAP+ cells in SVZa are not in active cell cycle (Tonchev et al., 2005), and a GFAP-enriched cellular population is thought to contain neural stem cells in adult human SVZa (Sanai et al., 2004). The partly overlapping transcription factor expression between Musashi1 and jIlIII-tubulin progenitors might be due to common molecular mechanisms involved in their regulation and/or might result from a lineage relationship between these two cell types. Further experiments are needed to clarify whether any of these possibilities might be true.

Different from Dlx1,5, Ngn1, Nkx2.2 or Olig3, the transcription factor Sox1 co-stained exclusively with jIlIII-tubulin. While the high Sox1/jIlIII-tubulin co-labeling is consistent with high Sox1/BrdU and BrdU/jIlIII-tubulin co-labeling (Tonchev et al., 2005) at long-term time points, the relatively high percentage of BrdU cells co-stained for Sox1 (about 50%) at the short-term (day 9) time-point with concomitant minimal Sox1/Musashi1 co-staining (<3%) is dis-
cordant with the high BrdU/Musashi1 co-expression characteristic for day 9 (Tonchev et al., 2005). The following cell phenotypes could be BrdU+/Sox1/Musashi1− cells on day 9: (i) the nearly 30% of the BrdU+ cells negative for Musashi1 on day 9 (Tonchev et al., 2005), and (ii) the approximately 10% of the Sox1+ cells with an unidentified (non-ßIII-tubulin/non-Musashi1) phenotype as shown in the present study. Moreover, the finding of cells stained for transcription factors but negative for either ßIII-tubulin or Musashi1 suggests phenotypical heterogeneity, a feature that is observed in multipotent progenitor cells (Pevny and Rao, 2003).

Non-primate mammalian models are essential in addressing fundamental stem cell issues. At the same time, primates appear to exhibit considerably lower levels of neurogenesis than non-primate mammals at both normal conditions (Kornack and Rakic, 1999) or in a context of injury-enhanced neurogenic response (Tonchev et al., 2003). The framework of molecular signals that may underlie this interspecies discrepancy is currently unknown. We observed certain similarities between our results in monkeys and studies using non-primate models with respect to transcription factor expression by adult SVZa progenitors. In particular, Emx2 and Sox2,3 were expressed by actively dividing sustained progenitors in monkey SVZa consistent with their previously reported expression in early multipotent progenitor/stem cells (Galli et al., 2002; Bylund et al., 2003; Graham et al., 2003; Ferri et al., 2004; Komitova and Eriksson, 2004), while Sox1 (but not Sox2,3) protein was predominantly localized in monkey neuronal progenitors consistent with its previously reported activity inducing neuronal commitment (Kan et al., 2004). At the same time, we noticed the following discrepancies between our results in monkeys and studies using non-primate animal models. First, Pax6 appeared to be predominantly localized to neuronal progenitors in adult mouse SVZa (Hack et al., 2004), while in monkey SVZa Pax6 was mainly positive in neural progenitors. Second, the transcription factors Dlx2 and Olig2 label transit-amplifying precursors in adult rodent SVZa (Doetsch et al., 2002; Hack et al., 2004) which are highly prolifera-

---

**Fig. 6.** Expression of Dlx proteins by SVZa progenitor cells. (A) Double-staining for Dlx1 (A1) and BrdU (A2), and overlay (A3), on day 9. A double-positive cluster is depicted (arrow). (B) Double-staining for Dlx2 (B1) and BrdU (B2), and overlay (B3), on day 9. Note that Dlx2+ cells (arrows) do not co-label with BrdU (arrowheads). (C) Double-staining for Dlx5 (C1) and BrdU (C2), and overlay (C3), on day 9. (D) Percentages (D1, D2) and absolute numbers (D3, D4) of BrdU+/Dlx1+ (D1, D3) and BrdU+/Dlx5+ (D2, D4) cells. *P<0.05 versus control. (E) Double-staining for Dlx1 (E1) and Musashi1 (Msi1, E2), and overlay (E3), on day 9. Note double-positive cells (e.g. arrows), and Dlx1+/Musashi1− cells exhibiting mitotic figures (arrowheads), entangled in a cluster. (F) Double-staining for Dlx1 (F1, arrows) and Ki67 (F2, arrowheads), and overlay (F3), on day 44. (G) Double-staining for Dlx1 (G1) and ßIII-tubulin (G2), and overlay (G3), on day 79. The Dlx1+ cluster is co-stained by ßIII-tubulin. (H) Triple-staining for Dlx5 (H1), BrdU (H2) and ßIII-tubulin (H3), and overlay (H4), on day 44. Note co-labeling in (ependymal layer is outlined by a dotted line). (I) Percentages of Dlx1+ (I1) or Dlx5+ (I2), cells co-expressing Musashi1 or ßIII-tubulin in the postischemic monkeys (for Dlx2 see text). Transcription factor-positive cells that were Musashi1−/ßIII-tubulin− are designated "other." Percentages in the control monkeys did not differ significantly from the postischemic ones. Scale bar~20 μm (A–C, H); 10 μm (E–G). Asterisk, lateral ventricle.
tive (Doetsch et al., 1997), while in our experiments we found very few BrdU+/H11001+/Dlx2+/H11001/ or BrdU+/H11001+/Olig2+/H11001/ cells. This suggests that monkey SVZa niche either has very few type C cells or that these cells do not express Dlx2 and Olig2. A detailed characterization of the cellular composition of adult monkey SVZa as done in rodents (Doetsch et al., 1997) is necessary to confirm or put aside this speculation.

The decision whether monkey SVZa progenitors will preserve their localization in the niche or will migrate away from SVZa might be coordinated by a balance of factors promoting or inhibiting proliferation and migration. Such putative factors are the neurotransmitters glutamate and GABA, which exhibit either stimulatory or inhibitory effects on the proliferation of embryonic precursor cells from ventricular zone or SVZ, respectively (Haydar et al., 2000). This suggests that distinct precursor cell populations respond to glutamate/GABA in different ways. In adult SVZa, glutamate and GABA have been reported to exert opposing effects on progenitor cells: glutamate activates (Brazel et al., 2005) while GABA inhibits (Liu et al., 2005) their proliferation. There-

Fig. 7. Expression of Olig proteins and Nkx2.2 by SVZa progenitor cells. (A) Double-staining for Olig1 (A1) and BrdU (A2), and overlay (A3), on day 9. The region depicted by a box is magnified in A4–A6 with orthogonal projections. (B) Double-staining for Olig3 (B1) and BrdU (B2), and overlay (B3), on day 44. Several BrdU+/Olig3- (arrowheads). A double-positive cell is depicted by arrows. (C) Double-staining for Olig2 (C1) and BrdU (C2), and overlay (C3), on day 9. A cluster positive for Olig2 (arrows) is not co-labeled by BrdU. A single cell in a neighboring BrdU- cluster is weakly positive for Olig2 (arrowheads). (D) Double-staining for Nkx2.2 (D1) and BrdU (D2), and overlay (D3), on day 9. Most cells are double-positive. (E) Percentages (E1–E3) and absolute numbers (E4–E6) of BrdU+/Olig1+ (E1, E4), BrdU+/Olig3+ (E2, E5) and Nkx2.2+ (E3, E6). *P<0.05 versus control. (F) Double-staining for Olig3 (F1) and Musashi1 (Msi1, F2), and overlay (F3), on day 9 (representative also for Olig1 and Nkx2.2). Double-labeled cells are depicted by arrows, while single-labeled cells (either Olig3+/Musi1- or Olig3-/Musi1+) are depicted by arrowheads. (G) Double-staining for Nkx2.2 (G1) and βIII-tubulin (G2), and overlay (G3), on day 23 (representative also for Olig3). (H) Staining for Olig2 (H1) and CNP (H2), on day 79. Two CNP+/Olig2- oligodendrocytes are co-labeled by Olig2. The cell depicted by an arrow is shown in a three-dimensional view with color separation in H3 (Olig2), H4 (CNP) and H5 (overlay). The image is representative also for Nkx2.2. (I) Double-staining for Olig1 (I1) and Ki67 (I2), on day 44. The cluster depicted by a box is magnified in I2 and I3 with color separation and orthogonal projections. (J) Percentages of Olig3+ (J1) or Nkx2.2+ (J2), cells co-expressing Musashi1 or βIII-tubulin in the postischemic monkeys (for Olig1,2 see text). Transcription factor-positive cells that were Musashi1-/βIII-tubulin- are designated "other." Percentages in the control monkeys did not differ significantly from the postischemic ones. Scale bar=50 μm (A); 10 μm (B–I). Asterisk, lateral ventricle.

A. B. Tonchev et al. / Neuroscience 139 (2006) 1355–13671364
fore, it is possible to speculate that these two endogenous amino acids may differentially affect neural or neuronal progenitors in monkey SVZa to achieve precursor cell proliferation/differentiation with either retention in SVZa or migration toward the olfactory bulb. Other extracellular signaling molecules might also be involved in precursor cell modulation by affecting transcription factor activity. For example, Ngn1 is required for erythropoietin-enhanced neurogenesis (Wang et al., 2006).

The present study had not aimed at deciphering the mechanisms for differential expression of transcription factors by neural progenitors with different proliferation or migration activities. Such mechanisms possibly include modulatory effects at promoter and/or enhancer regions of various transcription factors. For example, two distinct Sox2 enhancers are active in multipotent neural progenitors but cease to function in differentiated cells (Zappone et al., 2000; Miyagi et al., 2004). The mouse Pax6 gene has three promoters under the control of at least six different enhancers, directing Pax6 expression in distinct tissues (reviewed by Morgan, 2004). Given that different tissues, and even different progenitor cell types, require activation of selective regulatory elements, one may speculate that ischemia could differentially activate such elements in sustained or migrating SVZa progenitors. Unraveling the transcriptional network involved in the regulation of adult progenitor cell specification may lead to development of more effective strategies to direct these cells to adopt a selective cellular phenotype required in a specific brain lesion.

Acknowledgments—We thank Hirohide Takebayashi for the anti-Olig2 antibody and George N. Chaldakov for valuable discussions. The Japanese Ministries of Education, Culture, Sports, Science and Technology (Kiban B: 15390432) and Health, Labor and Welfare (H15-Kokoro-018), and the Bulgarian Ministry of Education and Science (L1311/03) supported this work.

REFERENCES


